ada tirzepatide noninferior, superior to semaglutide for T2DM Tirzepatida en el ADA 2026:

Relative contraindications requiring careful consideration and enhanced medical supervision include history of pancreatitis, severe gastrointestinal disease including gastroparesis, diabetic retinopathy (requires ophthalmologic monitoring during therapy), severe kidney disease, history of suicidal ideation or severe depression, gallbladder disease or history of cholecystitis, and age under 18 years

PMID 11516379

Imbalance of Th17/Treg is reported in different subtypes of autoimmune thyroid diseases

Supplementation with methionine-free formulas of amino acids is often needed to avoid protein deficiencies

DHEA, on the other hand, signals to increase dopamine levels in rapid, intense, short-lived bursts